Sotalol-d₆  (Synonyms: MJ 1999-d₆)

Sotalol-d₆ is the deuterium labeled Sotalol. Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3][4].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

278.40

C₁₂H₁₄D₆N₂O₃S

1246912-17-3

盐酸索他洛尔 d₆

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]

  [2]. Marta Reyes-Corral, et al. Differential Free Intracellular Calcium Release by Class II Antiarrhythmics in Cancer Cell Lines. J Pharmacol Exp Ther. 2019 Apr;369(1):152-162.  [Content Brief]

  [3]. Xiaomei Li, et al. Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia. Pediatr Cardiol. 2017 Oct;38(7):1450-1455.  [Content Brief]

  [4]. Kinga K Borowicz-Reutt, et al. Sotalol does not interfere with the antielectroshock action of selected second-generation antiepileptic drugs in mice.Pharmacol Rep. 2021 Apr;73(2):516-524.  [Content Brief]